SG11202011777PA - Adenoassociated virus vectors for the treatment of mucopolysaccharidoses type iv a - Google Patents

Adenoassociated virus vectors for the treatment of mucopolysaccharidoses type iv a

Info

Publication number
SG11202011777PA
SG11202011777PA SG11202011777PA SG11202011777PA SG11202011777PA SG 11202011777P A SG11202011777P A SG 11202011777PA SG 11202011777P A SG11202011777P A SG 11202011777PA SG 11202011777P A SG11202011777P A SG 11202011777PA SG 11202011777P A SG11202011777P A SG 11202011777PA
Authority
SG
Singapore
Prior art keywords
treatment
virus vectors
adenoassociated virus
mucopolysaccharidoses type
mucopolysaccharidoses
Prior art date
Application number
SG11202011777PA
Other languages
English (en)
Inventor
Tubert María Fátima Bosch
Clares Víctor Sanchez
Sanchez Albert Ribera
Virginia Areba Haurigot
Original Assignee
Esteve Pharmaceuticals Sa
UNIV AUTòNOMA DE BARCELONA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals Sa, UNIV AUTòNOMA DE BARCELONA filed Critical Esteve Pharmaceuticals Sa
Publication of SG11202011777PA publication Critical patent/SG11202011777PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/06—Sulfuric ester hydrolases (3.1.6)
    • C12Y301/06004—N-Acetylgalactosamine-6-sulfatase (3.1.6.4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
SG11202011777PA 2018-05-30 2019-05-27 Adenoassociated virus vectors for the treatment of mucopolysaccharidoses type iv a SG11202011777PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382373 2018-05-30
PCT/EP2019/063582 WO2019228950A1 (en) 2018-05-30 2019-05-27 Adenoassociated virus vectors for the treatment of mucopolysaccharidoses type iv a

Publications (1)

Publication Number Publication Date
SG11202011777PA true SG11202011777PA (en) 2020-12-30

Family

ID=62530167

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202011777PA SG11202011777PA (en) 2018-05-30 2019-05-27 Adenoassociated virus vectors for the treatment of mucopolysaccharidoses type iv a

Country Status (16)

Country Link
US (1) US20210214695A1 (pt)
EP (1) EP3802803A1 (pt)
JP (1) JP7369403B2 (pt)
KR (1) KR20210027266A (pt)
CN (1) CN113474453B (pt)
AR (1) AR115449A1 (pt)
AU (1) AU2019275969A1 (pt)
BR (1) BR112020024377A2 (pt)
CA (1) CA3101659A1 (pt)
CO (1) CO2020015942A2 (pt)
IL (1) IL279054A (pt)
MA (1) MA52737A (pt)
MX (1) MX2020012911A (pt)
PH (1) PH12020552041A1 (pt)
SG (1) SG11202011777PA (pt)
WO (1) WO2019228950A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3829619A4 (en) * 2018-07-27 2022-05-18 REGENXBIO Inc. TREATMENT OF MUCOPOLYSACCHARIDOSE IVA
BR112022015036A2 (pt) * 2020-01-29 2022-10-11 Regenxbio Inc Vírus adenoassociado recombinante (raav), composição farmacêutica, polinucleotídeo, plasmídeo de raav, célula ex vivo, método de produção de um raav, método para tratar um sujeito humano diagnosticado com mucopolissacaridose tipo iva (mps iva)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003255098A1 (en) * 2002-08-07 2004-02-25 Neworgen Limited A novel homo protein with cancer suppressing function and its coding sequence
US7972593B2 (en) * 2004-06-10 2011-07-05 Saint Louis University Delivery of therapeutic agents to the bone
SG11201609314XA (en) * 2014-05-14 2016-12-29 Esteve Labor Dr Adenoassociated virus vectors for the treatment of lysosomal storage disorders
AU2017333336B2 (en) * 2016-09-30 2023-11-09 Esteve Pharmaceuticals, S.A. Adenoassociated virus vectors for the treatment of mucopolysaccharidoses

Also Published As

Publication number Publication date
CN113474453B (zh) 2024-01-12
TW202016315A (zh) 2020-05-01
MX2020012911A (es) 2021-02-26
JP2021526023A (ja) 2021-09-30
BR112020024377A2 (pt) 2021-03-02
MA52737A (fr) 2021-04-14
CN113474453A (zh) 2021-10-01
PH12020552041A1 (en) 2021-06-28
KR20210027266A (ko) 2021-03-10
WO2019228950A1 (en) 2019-12-05
EP3802803A1 (en) 2021-04-14
JP7369403B2 (ja) 2023-10-26
IL279054A (en) 2021-01-31
AU2019275969A1 (en) 2020-12-24
CO2020015942A2 (es) 2021-03-08
AR115449A1 (es) 2021-01-20
CA3101659A1 (en) 2019-12-05
US20210214695A1 (en) 2021-07-15

Similar Documents

Publication Publication Date Title
ZA201708039B (en) Adenoassociated virus vectors for the treatment of mucopolysaccharidoses
HUS2200053I1 (hu) HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
PT3519569T (pt) Vetores de vírus adenoassociados para o tratamento de mucopolissacaridoses
EP3490987A4 (en) NOVEL THERAPEUTIC AGENTS FOR THE TREATMENT OF HBV INFECTION.
IL248538A0 (en) Vector viruses unrelated to the treatment of lysosomal storage disorders
EP3399972A4 (en) LOW DOSE THERAPEUTIC TREATMENT
ZA201900156B (en) Phosphoramidates for the treatment of hepatitis b virus
IL295609B1 (en) Hemisulfate nucleotide salt for treatment of hepatitis c virus
IL256327B (en) Pharmaceutical preparations for the treatment of viral problems of the eye
IL279054A (en) Adeno-associated virus vectors for the treatment of mucopolysacridoses type IV A
HUE049939T2 (hu) Liposzómák vírusfertõzések kezelésére
FI4021505T3 (fi) Lääke tartuntatautien hoitamiseksi
EP3094330A4 (en) Treatment of crohn's disease using low doses of laquinimod
EP3650015A4 (en) COMBINED DRUG PREPARATION FOR THERAPY OF VIRAL INFECTIONS